UK Anemia Drugs Market Analysis

UK Anemia Drugs Market Executive Summary

The UK Anemia Drugs market was valued at $415 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.9% from 2022 to 2030 and will reach $709 Mn in 2030. According to the World Bank, the United Kingdom is a powerful global commercial powerhouse with 67 million residents and a GDP of $3200 billion (2021). Despite its small size, the United Kingdom has the second-largest economy in Europe and will lead the G7 in GDP growth in 2021. (it is roughly the size of Oregon). The contribution of healthcare to GDP increased from 10.2% in 2019 to nearly 12.8% in 2020.

Anaemia is a condition in which the number of red blood cells or the concentration of hemoglobin in them is lower than usual. Haemoglobin is required to carry oxygen, and if you have too few or malformed red blood cells, or not enough hemoglobin, your blood's capacity to carry oxygen to the body's tissues will be reduced. Symptoms include weariness, weakness, dizziness, and shortness of breath, among others. Anaemia is predicted to affect 23% of pregnant women and 14% of non-pregnant women in the UK.

Market Dynamics

Market Growth Drivers

Anemia is a common condition that affects millions of people in the UK, and the prevalence is increasing due to factors such as aging populations, chronic diseases, and poor dietary habits. This trend is expected to continue in the coming years, driving demand for anemia drugs. ESAs are a type of anemia drug that stimulates the production of red blood cells. With the increasing prevalence of anemia, there is a growing demand for ESAs, which are commonly used to treat anemia associated with chronic kidney disease and chemotherapy-induced anemia. The pipeline of anemia drugs in development is robust, with many new drugs undergoing clinical trials. This is expected to lead to new and more effective treatments for anemia, which will drive growth in the market. Advances in technology, such as the development of long-acting ESAs and innovative drug delivery systems, are expected to improve the efficacy and convenience of anemia treatments. This is expected to drive demand for anemia drugs in the UK market. Improved screening and diagnostic techniques are leading to earlier detection and diagnosis of anemia, which will drive demand for anemia drugs as more patients seek treatment.

Market Restraints

Health and care services in the United Kingdom are confronting enormous problems, including persistent staffing shortages and a growing backlog of unmet healthcare needs. These issues have been compounded by the pandemic and are affecting other countries as well. Yet, how much a country spends on health is critical for the sustainability of its health-care system and readiness for future surges in demand (expected and unexpected). Apart from this, the UK government is facing increasing pressure to reduce healthcare costs, and this is leading to efforts to reduce the price of drugs. Anemia drugs are no exception, and manufacturers may find it difficult to maintain profitability if prices continue to be squeezed. Some anemia drugs have been associated with safety concerns, particularly in the case of ESAs, which have been linked to an increased risk of cardiovascular events. This has led to greater caution in prescribing these drugs, which may limit the market size. Despite the prevalence of anemia, there is still a lack of awareness and education about the condition among healthcare professionals and the general public. This may limit the number of patients seeking treatment, particularly in cases where anemia is mild or asymptomatic.

Competitive Landscape

Key Players

• Pfizer
• Roche
• Amgen
• GlaxoSmithKline
• Johnson & Johnson
• Alcon Laboratories
• FibroGen
• Vifor Pharma Group
• Akebia Therapeutics
• ALK-Abelló

Healthcare Policies and Regulatory Landscape

The National Health Service (NHS) is a government-sponsored universal healthcare system in the United Kingdom. The NHS is a collection of publicly funded healthcare systems in the United Kingdom. It encompasses NHS England, NHS Scotland, NHS Wales, and Health and Social Care in Northern Ireland. Citizens are entitled to healthcare under this system, but they can also purchase private health insurance. The NHS Plan promises people greater control and information, more hospitals and beds, more physicians and nurses, much-reduced appointment wait times, better healthcare for elderly patients, and tougher requirements for NHS organizations.

The NHS commissioning policies play a key role in shaping the provision of anemia treatments. These policies determine which treatments are available to patients and how they are funded. Patient access schemes are agreements between drug manufacturers and the NHS that provide discounts or rebates on the cost of drugs. These schemes are designed to improve patient access to treatments while ensuring value for money for the NHS.

Reimbursement Scenario

The National Institute for Health and Care Excellence (NICE) evaluates the clinical and cost-effectiveness of drugs in the UK. The assessment considers the evidence on the effectiveness of the drug and the cost of the drug compared to other treatments. NICE provides guidance on the use of the drug. This guidance informs the decisions of healthcare professionals and commissioners on the use of the drug and whether it should be funded by the NHS. The NHS commissioning policies determine which treatments are available to patients and how they are funded. Commissioning policies are informed by NICE guidance and consider the clinical and cost-effectiveness of the drug. Drug manufacturers can offer patient access schemes that provide discounts or rebates on the cost of the drug. These schemes are designed to improve patient access to treatments while ensuring value for money for the NHS.